Matthias Mayerhofer

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.

Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis.

Journal: Blood

Published: March 20, 2023

A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition.

A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition.

Journal: Frontiers in pediatrics

Published: September 27, 2019

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.

Journal: Haematologica

Published: January 29, 2019

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis.

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis.

Journal: Clinical chemistry

Published: June 14, 2017

CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Journal: Blood

Published: September 08, 2016

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.

Journal: Cancer cell

Published: August 10, 2016

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Journal: Blood

Published: March 31, 2015

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Journal: American journal of cancer research

Published: November 12, 2014

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 07, 2014

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Journal: Blood

Published: April 30, 2014

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.

Journal: Journal of leukocyte biology

Published: September 21, 2013

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.

Journal: Cancer cell

Published: November 23, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026